<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05126563</url>
  </required_header>
  <id_info>
    <org_study_id>HBPCOVID02</org_study_id>
    <nct_id>NCT05126563</nct_id>
  </id_info>
  <brief_title>Randomized Double-Blind Phase 2 Study of Allogeneic HB-adMSCs for the Treatment of Chronic Post-COVID-19 Syndrome</brief_title>
  <acronym>HBPCOVID02</acronym>
  <official_title>A Randomized, Double-blinded, Single-center, Phase 2 Efficacy, and Safety Study of Allogeneic HB-adMSCs for the Treatment of Patients With Chronic Post-COVID-19 Syndrome.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hope Biosciences Stem Cell Research Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hope Biosciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will enroll up to 80 subjects with Chronic Post COVID-19 Syndrome. Subjects will&#xD;
      receive four intravenous injections of either allogeneic HB-adMSC's or a placebo over 10&#xD;
      weeks with two follow-up visits and an end of study visit at week 26.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Active Product: HB- adMSCs (Hope Biosciences adipose-derived mesenchymal stem cells -&#xD;
      allogeneic) Dose: 200 million Route: Intravenous Regimen: Weeks 0, 2, 6, and 10. Placebo:&#xD;
      Saline Solution 0.9% Dose: N/A Route: Intravenous Regimen: Weeks 0, 2, 6, and 10.Duration of&#xD;
      administration 1 hour Laboratory Samples. Screening, Week 0, 6, and 26. Visits by Weeks&#xD;
      Screening Week 0 - Infusion 1 Week 2 - Infusion 2 Week 6 - Infusion 3 Week 10 - Infusion 4&#xD;
      Week 14 - Follow Up 1 Week 20 - Follow Up 2 Week 26 - End of Study&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">December 20, 2021</start_date>
  <completion_date type="Anticipated">December 20, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 20, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized Double-Blind</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Amber bags will be used to 'blind' the participant and investigator to which group the subject belongs in.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Visual Analog Scale of Neurological Symptoms. - Extreme fatigue</measure>
    <time_frame>Baseline to Weeks 26</time_frame>
    <description>Clinically significant changes in Visual Analog Scale - Extreme fatigue</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Visual Analog Scale of Neurological Symptoms. - Brain fog</measure>
    <time_frame>Baseline to Weeks 26</time_frame>
    <description>Clinically significant changes in Visual Analog Scale - Brain fog</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Visual Analog Scale of Neurological Symptoms. - Headache</measure>
    <time_frame>Baseline to Weeks 26</time_frame>
    <description>Clinically significant changes in Visual Analog Scale - Headache</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Visual Analog Scale of Neurological Symptoms. - Sleep disturbances</measure>
    <time_frame>Baseline to Weeks 26</time_frame>
    <description>Clinically significant changes in Visual Analog Scale - Sleep disturbances</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Visual Analog Scale of Neurological Symptoms. - Loss of taste</measure>
    <time_frame>Baseline to Weeks 26</time_frame>
    <description>Clinically significant changes in Visual Analog Scale - Loss of taste</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Visual Analog Scale of Neurological Symptoms. - Loss of smell</measure>
    <time_frame>Baseline to Weeks 26</time_frame>
    <description>Clinically significant changes in Visual Analog Scale - Loss of smell</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of treatment-emergent Adverse Event (TEAEs).</measure>
    <time_frame>Baseline to Weeks 26</time_frame>
    <description>Treatment-emergent Adverse Event.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of treatment-emergent Serious Adverse Events (SAEs).</measure>
    <time_frame>Baseline to Weeks 26</time_frame>
    <description>SSAEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AEs of special interest (serious or non-serious) - thromboembolic events.</measure>
    <time_frame>Baseline to Weeks 26</time_frame>
    <description>Incidence of thromboembolic events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AEs of special interest (serious or non-serious) - thromboembolism of the extremities.</measure>
    <time_frame>Baseline to Weeks 26</time_frame>
    <description>Incidence and risk of AEs of special interest (serious or non-serious), including peripheral events defined as, thromboembolism of the extremities.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AEs of special interest (serious or non-serious) - infections.</measure>
    <time_frame>Baseline to Weeks 26</time_frame>
    <description>Incidence and risk of AEs of special interest (serious or non-serious), including infections.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AEs of special interest (serious or non-serious) - hypersensitivities.</measure>
    <time_frame>Baseline to Weeks 26</time_frame>
    <description>Incidence and risk of AEs of special interest (serious or non-serious), including hypersensitivities.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Laboratory values. - CBC.</measure>
    <time_frame>Baseline to Weeks 26</time_frame>
    <description>Clinically significant changes in CBC values.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Laboratory values. - CMP.</measure>
    <time_frame>Baseline to Weeks 26</time_frame>
    <description>Clinically significant changes in CMP values.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Laboratory values. - Coagulation Panel.</measure>
    <time_frame>Baseline to Weeks 26</time_frame>
    <description>Clinically significant changes in Coagulation Panel values.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Vital Signs. - Respiratory Rate (breaths per minute)</measure>
    <time_frame>Baseline to Weeks 26</time_frame>
    <description>Clinically significant changes in Respiratory Rate.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Vital Signs. - Heart Rate (beats per minute)</measure>
    <time_frame>Baseline to Weeks 26</time_frame>
    <description>Clinically significant changes in Heart Rate.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Vital Signs. - Body Temperature (Fahrenheit )</measure>
    <time_frame>Baseline to Weeks 26</time_frame>
    <description>Clinically significant changes in Body Temperature.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Vital Signs. - Blood Pressure (mmHg)</measure>
    <time_frame>Baseline to Weeks 26</time_frame>
    <description>Clinically significant changes in Blood Pressure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Weight in lb.</measure>
    <time_frame>Baseline to Weeks 26</time_frame>
    <description>Clinically significant changes in Weight.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Physical examination results. - General</measure>
    <time_frame>Baseline to Weeks 26</time_frame>
    <description>Clinically significant changes in general physical examination results.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Physical examination results. - Body Systems</measure>
    <time_frame>Baseline to Weeks 26</time_frame>
    <description>Clinically significant changes in Body Systems physical examination results.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Subject's energy - Fatigue Assessment form.</measure>
    <time_frame>Baseline to Weeks 26</time_frame>
    <description>Clinically significant changes in Fatigue Assessment form.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Visual Analog Scale of non -Neurological Symptoms. - Dyspnea a rest</measure>
    <time_frame>Baseline to Weeks 26</time_frame>
    <description>Clinically significant changes in Dyspnea a rest</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Visual Analog Scale of non -Neurological Symptoms. - Dyspnea with activity</measure>
    <time_frame>Baseline to Weeks 26</time_frame>
    <description>Clinically significant changes in Dyspnea with activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Visual Analog Scale of non -Neurological Symptoms. - Cough</measure>
    <time_frame>Baseline to Weeks 26</time_frame>
    <description>Clinically significant changes in Cough</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Visual Analog Scale of non -Neurological Symptoms. - Body aches</measure>
    <time_frame>Baseline to Weeks 26</time_frame>
    <description>Clinically significant changes in Body aches</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Visual Analog Scale of non -Neurological Symptoms. - Joint pain</measure>
    <time_frame>Baseline to Weeks 26</time_frame>
    <description>Clinically significant changes in Joint pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Subject's quality of life - Short Form 36 Health Survey Questionnaire</measure>
    <time_frame>Baseline to Weeks 26</time_frame>
    <description>Clinically significant changes in Short Form 36 Health Survey Questionnaire pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Subject's level of depression - PHQ 9 scale.</measure>
    <time_frame>Baseline to Weeks 26</time_frame>
    <description>Clinically significant changes in PHQ 9 scale. pain</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Post COVID-19 Syndrome</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>HB-ad MSC's allogeneic</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sterile Normal Saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HB-adMSCs (allogeneic)</intervention_name>
    <description>HB-adMSCs allogenic</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Hope Biosciences adipose derived mesenchymal stem cells</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo comarator</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sterile Normal Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1 Male and female participants 18 - 70 years of age. 2. Participants in the study have&#xD;
        proof of Post COVID-19 Syndrome in their medical records. 3. Study participants must have&#xD;
        been diagnosed with Chronic post-COVID-19 syndrome for at least twelve weeks before&#xD;
        enrollment in the clinical trial. 4. The study participant is experiencing one or more&#xD;
        neurological symptoms for at least 12 weeks, either continually or intermittently, with&#xD;
        relapses not experienced pre-illness that interferes with regular daily activities.&#xD;
        Symptoms must be new symptoms or dramatic worsening of preexisting symptoms, i.e., the&#xD;
        subject didn't have symptoms and had not sought medical treatment for the symptoms before&#xD;
        COVID-19, or the symptoms are dramatically worse (in severity and frequency). At least one&#xD;
        symptom must have a severity of &quot;5cm&quot; on the neurological symptom VAS at screening. See the&#xD;
        list of symptoms below:&#xD;
&#xD;
        Extreme fatigue: Feeling overtired with low energy and a strong desire to sleep Brain Fog:&#xD;
        A diminished mental capacity marked by the inability to concentrate, think or reason&#xD;
        clearly interferes with daily activities.&#xD;
&#xD;
        Headache: Sharp or dull reoccurring or intermittent that were not present pre-illness.&#xD;
&#xD;
        Sleep Issues: Any sleep disturbances in sleep quality that makes sleep seem inadequate or&#xD;
        unrefreshing like insomnia or hypersomnia.&#xD;
&#xD;
        Loss of Taste/Smell: A diminished sense of taste or smell.&#xD;
&#xD;
        5. Study participants should be able to read, understand, and provide written consent.&#xD;
&#xD;
        6. Female study participants should not be pregnant or plan to become pregnant during study&#xD;
        participation and six months after the last investigational product administration.&#xD;
&#xD;
        7. If their sexual partners can become pregnant, male participants should use a method of&#xD;
        contraception during study participation and for six months after the last administration&#xD;
        of the experimental drug. * 8. The study participant is able and willing to comply with the&#xD;
        requirements of this clinical trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The subject is unable to provide informed consent or to comply with study&#xD;
             requirements.&#xD;
&#xD;
          2. A study participant has currently been diagnosed with active COVID-19 disease, defined&#xD;
             as ongoing symptoms related to acute infection (such as fever or chills, cough,&#xD;
             shortness of breath, or difficulty breathing, among other symptoms), and evidence of a&#xD;
             positive RT-PCR SARS- CoV-2.&#xD;
&#xD;
          3. The subject is unwilling to agree to the use of acceptable methods of contraception *&#xD;
             throughout the study and for six months after the last dose of the investigational&#xD;
             product.&#xD;
&#xD;
          4. Pregnancy, lactation. Women of childbearing age who are not pregnant but do not take&#xD;
             adequate contraceptive measures. *&#xD;
&#xD;
          5. The study participant has a history of addiction or dependency, or he or she is&#xD;
             currently abusing or using substances.&#xD;
&#xD;
          6. Study participant has any active malignancy, including but not limited to evidence of&#xD;
             cutaneous basal, squamous cell carcinoma, or melanoma.&#xD;
&#xD;
          7. The study participant has one or more significant concurrent medical conditions&#xD;
             (verified by medical records), including the following:&#xD;
&#xD;
               -  Diabetes Mellitus (DM) Poorly controlled diabetes mellitus (PCDM), defined as a&#xD;
                  history of deficient standard of care treatment or pre-prandial glucose &gt;130mg/dl&#xD;
                  during screening visit or post-prandial glucose &gt;200mg/dl.&#xD;
&#xD;
               -  Chronic kidney disease (CKD)&#xD;
&#xD;
               -  Medical History of Chronic kidney disease (CKD) diagnosis or screening results of&#xD;
                  eGFR &lt; 59mL/min/1.73m2.&#xD;
&#xD;
               -  Heart Failure Presence of New York Heart Association (NYHA) Class III/IV heart&#xD;
                  failure during the screening visit.&#xD;
&#xD;
               -  Myocardial Infarction Medical history of myocardial infarction in any of the&#xD;
                  different types, such as ST-elevation myocardial infarction (STEMI) or&#xD;
                  non-ST-elevated myocardial infarction (NSTEMI), coronary spasm, or unstable&#xD;
                  angina.&#xD;
&#xD;
               -  High Blood Pressure Medical history of uncontrolled high blood pressure is&#xD;
                  defined as a deficient standard of care treatment or blood pressure &gt; 180/120&#xD;
                  mm/Hg during the screening visit.&#xD;
&#xD;
               -  Other diseases Medical history of inherited thrombophilias, cancer of the lung,&#xD;
                  brain, lymphatic, gynecologic system (ovary or uterus), or gastrointestinal tract&#xD;
                  (like pancreas or stomach).&#xD;
&#xD;
               -  Other conditions Lower extremity paralysis due to spinal cord injury, fracture of&#xD;
                  the pelvis, hips or femur or recent major general surgery (within 12 months&#xD;
                  before the Screening).&#xD;
&#xD;
          8. Study participant has received any stem cell treatment within 12 months before the&#xD;
             first dose of the investigational product other than stem cells produced by Hope&#xD;
             Biosciences.&#xD;
&#xD;
          9. The study participant has received an experimental drug within 12 months before the&#xD;
             first dose of the investigational product. (Except for COVID-19 vaccinations)&#xD;
&#xD;
         10. Study participant has a laboratory abnormality during screening, including the&#xD;
             following:&#xD;
&#xD;
               -  White blood cell count &lt; 3000/mm3&#xD;
&#xD;
               -  Platelet count &lt; 80,000mm3&#xD;
&#xD;
               -  Absolute neutrophil count &lt; 1500/mm3&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) 10 upper limit&#xD;
                  of normal (ULN) x 1.5&#xD;
&#xD;
               -  The study participant has any other laboratory abnormality or medical condition&#xD;
                  that, in the investigator's opinion, poses a safety risk or will prevent the&#xD;
                  subject from completing the study.&#xD;
&#xD;
         11. The study participant has any known ongoing infection, including TB, CMV, EBV, HSV,&#xD;
             VZV, hepatitis virus, toxoplasmosis, HIV, syphilis infections, hepatitis B surface&#xD;
             antigen-positive, or hepatitis C PCR positivity.&#xD;
&#xD;
         12. The study participant is unlikely to complete the study or adhere to the study&#xD;
             procedures.&#xD;
&#xD;
         13. The study participant has a previously diagnosed psychiatric condition that may affect&#xD;
             self-assessments in the investigator's opinion.&#xD;
&#xD;
         14. Study participants with any systemic infection requiring treatment with antibiotics,&#xD;
             antivirals, or antifungals within 30 days before the first dose of the investigational&#xD;
             product.&#xD;
&#xD;
         15. Male study participants expect to donate sperm during the trial or within six months&#xD;
             after the last dose. Female patients intend to donate eggs or have IVF treatment&#xD;
             during the trial or within six months after the last dose.&#xD;
&#xD;
         16. Study participants who the Investigator determines to be unsuitable for study&#xD;
             enrollment for other reasons.&#xD;
&#xD;
         17. The subject has recently been diagnosed with an unstable Chronic obstructive pulmonary&#xD;
             disease (COPD) as defined by patients who experience frequent or severe exacerbations&#xD;
             and a faster decline in pulmonary function.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sherry Diers, RN</last_name>
    <phone>3469000340</phone>
    <phone_ext>101</phone_ext>
    <email>Sherry@hopebio.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David Gonzalez, RN</last_name>
    <phone>3469000340</phone>
    <phone_ext>101</phone_ext>
    <email>David@hopebio.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hope Biosciences Stem Cell Research Foundation</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77478</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sherry Diers, RN</last_name>
      <phone>346-900-0340</phone>
      <phone_ext>101</phone_ext>
      <email>Sherry@hopebio.org</email>
    </contact>
    <contact_backup>
      <last_name>David Gonzalez, RN</last_name>
      <phone>3469000340</phone>
      <phone_ext>101</phone_ext>
      <email>David@hopebio.org</email>
    </contact_backup>
    <investigator>
      <last_name>Thanh C Cheng, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Djamchid Lotfi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 12, 2021</study_first_submitted>
  <study_first_submitted_qc>November 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

